Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis

Kai Deng | Qinghong Fan | Yanhong Yang | Xizi Deng | Ruiying He | Yizhou Tan | Yun Lan | Xilong Deng | Yuejun Pan | Yaping Wang | Yujuan Guan | Huiyuan Liu | Fengjuan Chen | Xiaoneng Mo | Xinghua Tan | Chun Luo | Xueliang Wen | Ying Liu | Jinxin Liu | Lieguang Zhang | Xiaoping Tang | Fengyu Hu | Feng Li

Infectious Diseases Institute, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, China

Correspondence
Xiaoping Tang, Fengyu Hu, and Feng Li, Infectious Diseases Institute, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou 510060, China. Email: tangxiaopinggz@163.com (X. T.); gz8hhly@126.com (F. H.), and gz8h_lifeng@126.com (F. L.)

Funding information
Guangdong Provincial Department of Science and Technology Fund, Grant/Award Number: 2020B1111330002

Abstract
To investigate the dynamic changes of Krebs von den Lungen-6 (KL-6) among patients with coronavirus disease 2019 (COVID-19) and the role of KL-6 as a noninvasive biomarker for predicting long-term lung injury, the clinical information and laboratory tests of 166 COVID-19 patients were collected, and a correlation analysis between KL-6 and other parameters was conducted. There were 17 (10.2%, 17/166) severe/critical and 149 (89.8%, 149/166) mild COVID-19 patients in our cohort. Serum KL-6 was significantly higher in severe/critical COVID-19 patients than in mild patients (median 898.0 vs. 451.2 U/ml, \(p < .001\)). KL-6 was next confirmed to be a sensitive and specific biomarker for distinguishing mild and severe/critical patients and correlate to computed tomography lung lesions areas. Serum KL-6 concentration during the follow-up period (>100 days postonset) was well correlated to those concentrations within 10 days postonset (Pearson \(r = .867, p < .001\)), indicating the prognostic value of KL-6 levels in predicting lung injury after discharge. Finally, elevated KL-6 was found to be significantly correlated to coagulation disorders, and T cells subsets dysfunctions. In summary, serum KL-6 is a biomarker for assessing COVID-19 severity and predicting the prognosis of lung injury of discharged patients.

KEYWORDS
COVID-19, KL-6, lung injury, prognosis

1 INTRODUCTION

The coronavirus disease 2019 (COVID-19), caused by the highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a global pandemic and claimed over 1 million lives by October 31.\(^1\) The clinical spectrum of COVID-19 ranges from asymptomatic, to mild, to moderate, to severe and critical. Severe and critical patients are characterized by respiratory failure and require oxygen supply and even invasive mechanical ventilation. Although SARS-CoV-2 infects could potentially infect various tissues and cells via its receptors angiotensin-converting enzyme 2 (ACE2) and TMPRSS2,\(^2\) the virus predominately replicates and causes mainly lung injury in clinical observations. Electron microscopy observed the SARS-CoV-2 replication foci in bronchial and lung type II pneumocytes and the direct viral-induced cell lysis.\(^3\) Viral invasion in the lung also alerts the innate immune cells per se, which subsequently sends danger signals and recruit other immune cells to the lung for combating the invader virus. Excessive accumulation and activation

Kai Deng, Qinghong Fan, and Yanhong Yang contributed equally to this study.
of tons of immune cells in the lung inevitably produce cytokines and chemical mediators, which evoke the “cytokine storm” affecting other organs especially in severe/critical patients. Notably, coagulation abnormalities, such as elevated d-dimer and lactate dehydrogenase (LDH), prolonged prothrombin time (PT) are identified to be associated with poor prognosis and high mortality. However, easy and affordable biomarkers indirectly reflecting lung injury are rarely employed to evaluate the long-term outcome, and the relationship between lung injury and coagulation abnormalities in COVID-19 patients remains uninvestigated.

Krebs von den Lungen-6 (KL-6) is a glycoprotein mainly produced by damaged or regenerating lung type II pneumocytes. Elevated serum KL-6 concentrations have been utilized as a surrogate of interstitial lung diseases for more than 2 decades. Recently KL-6 was reported to be associated with COVID-19 severity. A significantly elevated level of KL-6 was suggested to indicate a severe status and poor prognosis. However, their conclusions were only based on a small cohort of 22 patients and 2 severe patients, respectively. Further confirmation of the prognostic value of KL-6 in a larger and longitudinal cohort with a comprehensive analysis is critical but unfortunately missing. Here, we profiled the longitudinal and dynamic changes of KL-6 in 166 COVID-19 patients from symptom onset to 6 months postdischarge, and also analyzed the association between KL-6 and coagulation and immune parameters.

2 MATERIALS AND METHODS

2.1 Study population

One hundred sixty-six COVID-19 patients hospitalized at Guangzhou Eighth People’s Hospital were included in this study. Patients were diagnosed as mild or severe/critical according to Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (seventh edition, General Office of National Health Commission). The patient clinic and laboratory tests were collected from the medical records of Guangzhou Eighth People’s Hospital. The study was approved by the ethical committee of Guangzhou Eighth People’s Hospital (No. 202001134). Written consent was obtained from all patients.

2.2 KL-6 assay

Serum KL-6 was measured by a commercial Diagnostic Kit (Cat. 200309; Kangrun Biotech) based on a standard curve of serial dilutions of KL-6 standard sample with Kaeser 1000 Automatic Chemiluminescence Immunoassay Analyzer provided by the Kangrun Biotech.

2.3 Flow cytometry analysis

Five-hundred microliters of peripheral blood mononuclear cells were isolated from 10 ml of whole blood of patients and processed with flow cytometry with a panel of antibodies including CD3-Pacific-Blue anti-human antibody (B286012; Biolegend), CD4-APC/cy7 anti-human antibody (B299289; Biolegend), CD8-BV510 anti-human antibody (B303256; Biolegend), CD161-FITC anti-human antibody (B302548; Biolegend), CD25-APC anti-human antibody (B294860; Biolegend), CD127-PE/cy7 anti-human antibody (B286366; Biolegend), CXCR5-Perp/cy5.5 anti-human antibody (B295344; Biolegend), and PD-1-PE anti-human antibody (B304891; Biolegend). Data were analyzed using FlowJo software (BD-Biosciences).

2.4 Statistics analysis

Continuous variables were expressed as medians (interquartile range) or mean ± SEM. Categorical variables were summarized as the counts and percentages in each category. Student’s t tests were applied to continuous variables, the Mann–Whitney U test and \( \chi^2 \) test were used for categorical variables as appropriate. Areas under the receiver operating characteristic (ROC) curves (area under the curve) of KL-6, LDH, and d-dimer were assessed for distinguishing mild and severe/critical patients. Pearson’s or Spearman’s rank correlation was used to explore the correlations between different parameters as appropriate. A linear regression model was established to predict the KL-6 levels at greater than 100 days postonset based on the values of KL-6 within 10 days postonset. \( p < .05 \) was considered statistically significant. Statistical analysis was performed with IBM SPSS Statistics 26. Graphic representations were performed with GraphPad Prism 8 software.

3 RESULTS

3.1 Serum KL-6 was substantially elevated in severe/critical COVID-19 patients

In total, 166 COVID-19 patients were enrolled in this study (Table 1). A total of 149 (89.8%) patients were diagnosed as mild and 17 (10.2%) were as severe/critical. To get the base level of KL-6 level in the whole population, we measured the samples from 59 healthy volunteers (\( n = 59 \)) and found that the median value of serum KL-6 was 180.9 U/ml (Figure 1 and Table S1). Patients with COVID-19 had significantly higher levels of KL-6 compare to healthy volunteers (\( p < .001 \), Figure 1). The severe/critical patients had even significantly higher levels of serum KL-6 than the mild (median 898.0 vs. 452.1 U/ml, \( p < .001 \), Table 1 and Figure 1). We found that KL-6 increased from symptom onset, reached a peak approximately within a month, and then gradually decreased (Figure S1). How long it requires to reach KL-6 peak will be critical to reflect the extent and the speed of lung injury in patients with COVID-19. Here, we defined the day with the highest KL-6 among more than three detections within 1 month postonset as the peak day. We found a delayed
| Parameters | Mild cases (n = 149) | Severe/critical cases (n = 17) | p  |
|------------|----------------------|--------------------------------|----|
| Age, years | 48.0 (34.5–62.0)     | 55.0 (53.0–68.0)                | <.001 |
| Sex        |                      |                                |    |
| Male       | 65 (43.6%)           | 9 (52.9%)                      | .464 |
| Female     | 84 (56.4%)           | 8 (47.1%)                      |    |
| Outcome    |                      |                                | .102 |
| Discharged | 149 (100%)           | 16 (94.1%)                     |    |
| Hospitalized | 0 (0%)              | 1 (5.9%)                       |    |
| Hospital stay, days | 18.0 (13.5–26.0) | 23.0 (14.5–37.0)                | .213 |
| KL-6, U/ml | 452.1 (325.6–641.3)  | 898.0 (567.7–1278.9)           | <.001 |
| LDH, U/L   | 180.0 (151.0–230.0)  | 266.0 (229.0–398.5)            | .001 |
| CK, U/L    | 52 (36–77)           | 59 (26–120)                    | .344 |
| PT, s      | 13.6 (13.2–14.1)     | 15.3 (14.4–16.0)               | .754 |
| D-dimer, µg/L | 1210 (800–1640)   | 3380 (2368–10165)              | .003 |
| PTA, %     | 94.0 (87.0–100.0)    | 74.0 (68.3–82.8)               | <.001 |
| INR        | 1.04 (1.00–1.09)     | 1.20 (1.12–1.27)               | <.001 |
| TT, s      | 16.0 (15.5–16.7)     | 18.0 (16.1–22.8)               | .106 |
| APTT, s    | 38.7 (36.1–42.5)     | 54.4 (39.6–65.2)               | .002 |
| Fib, g/L   | 3.98 (3.17–4.88)     | 5.05 (4.32–6.04)               | <.001 |
| FDP, mg/L  | 1.78 (1.30–2.82)     | 6.95 (5.15–18.84)              | .011 |
| PLT, 10^9/L| 210.5 (170.8–254.3)  | 192.0 (117.5–272.5)            | .766 |
| MPV, fl    | 10.4 (9.7–11.0)      | 11.7 (9.9–12.6)                | <.001 |
| PLT-PCT, % | 0.22 (0.18–0.27)     | 0.23 (0.15–0.30)               | .969 |
| PDW, %     | 11.8 (10.4–13.4)     | 14.3 (11.1–16.2)               | <.001 |
| P-LCR, %   | 27.6 (22.1–32.8)     | 38.0 (23.4–44.6)               | <.001 |
| RBC, 10^12/L| 4.26 (3.88–4.74)    | 2.88 (2.55–3.82)               | .216 |
| HGB, g/L   | 130.5 (119.0–143.0)  | 98.0 (75.5–117.0)              | <.001 |
| Hct, %     | 38.5 (35.5–41.7)     | 28.2 (23.1–34.8)               | <.001 |
| Urea, µmol/L| 3.99 (3.43–4.82)    | 10.64 (4.64–18.29)             | .025 |
| UA, mmol/L | 288.7 (235.0–346.8)  | 189.3 (88.0–231.0)             | .024 |
| Cr, µmol/L | 66.9 (55.1–79.6)     | 83.8 (49.3–164.6)              | .005 |
| Cys-C, mg/L| 0.88 (0.77–0.99)     | 2.21 (1.02–4.29)               | <.001 |
| eGFR, ml/min/1.73 m² | 129.1 (108.9–149.2) | 82.3 (35.8–162.1)              | .005 |
| aCL IgG, CPLU/ml | 2.30 (1.57–3.56)  | 3.28 (2.66–4.38)               | .283 |
| CD3+ T, %  | 58.4 (45.9–66.1)     | 21.6 (11.6–44.8)               | <.001 |
| CD3+CD4+ T, % | 56.3 (44.9–66.0)  | 44.4 (29.6–57.5)               | .030 |
| Tregs, %   | 5.7 (4.7–7.7)        | 9.3 (5.3–12.6)                 | .001 |
| CD4+CD161+ T, % | 12.6 (9.0–18.7)  | 12.2 (9.2–18.7)                | .869 |
| CD3+CD8+ T, % | 36.8 (28.6–48.3)  | 44.0 (37.2–55.9)               | .040 |
| CD8+CD161+ T, % | 9.4 (6.8–12.4)   | 22.6 (15.0–35.3)               | <.001 |
| CD4/CD8+ % | 1.5 (0.9–2.3)        | 1.0 (0.5–1.5)                  | .017 |
| CD4/CD+1+ T, % | 10.4 (8.0–14.6)  | 20.5 (11.8–30.8)               | <.001 |
| CD4+CXCR5+ T, % | 15.2 (11.8–20.6)  | 7.8 (3.8–16.6)                 | .005 |

Note: Data are median (IQR) or n (%). p values were calculated by Mann–Whitney U test, Student’s t test, or χ² test, as appropriate. Abbreviations: aCL IgG, anti-cardiolipin immunoglobulin G; APTT, activated partial thromboplastin time; CD, cluster of differentiation; CK, creatine kinase; COVID-19, coronavirus disease 2019; Cr, creatinine; CXCR5, chemokine receptor type 5; Cys-C, cystatin C; eGFR, estimated glomerular filtration rate; FDP, fibrin degradation product; Fib, fibrinogen; Hct, hematocrit; HGB, hemoglobin; INR, international normalized ratio; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; MPV, mean platelet volume; PD-1, programmed death-1; PDW, platelet distribution width; P-LCR, platelet-large cell ratio; PLT, platelet; PLT-PCT, plateletcrit; PT, prothrombin time; PTA, prothrombin time activity; RBC, red blood cells; Tregs, regulatory T cells; TT, thrombin time; UA, uric acid.
peak day for severe/critical patients compared to the mild (21.8 ± 6.0 vs. 15.3 ± 7.0 [mean ± SEM] days, p = .015, Figure S2).

Besides, we observed that it took 17.5 ± 1.9 (mean ± SEM) days for mild and 10.6 ± 1.8 (mean ± SEM) days for severe/critical patients to reach a higher level of KL-6 (cutoff = 600 U/ml, p = .011, Figure S3). Altogether, our results indicated that lung injury deteriorated rapidly and that continuous and progressive lung injury among severe/critical COVID-19 patients.

Recently serum KL-6 as well as other parameters, for example, D-dimer and LDH, were suggested as a biomarker of COVID-19 severity, but the conclusion was drawn from a small cohort (n = 22 or 2). In our cohort (n = 166), ROC analysis supported the use of serum KL-6 distinguishing mild and severe/critical patients (Table S2 and Figure S4). The AUC of KL-6 was 0.793 (95% confidence interval: 0.718–0.868, p < .001) and the best cutoff value was 642.3 U/ml (75.3% sensitivity and 73.3% specificity) or 788.2 U/ml (86.4% sensitivity and 62.2% specificity).

3.2 | Early serum KL-6 predicted the prognosis of lung injury of discharged COVID-19 patients

For each patient with COVID-19, the KL-6 level at greater than 100 days postonset was linearly correlated to his KL-6 level within 10 days postonset (Pearson r = .867, p < .001). A linear regression model predicted KL-6 at greater than 100 days postonset = 87.729 + 0.563 × (KL-6 within 10 days postonset) (r = .867, p < .001, Figure 2). For each COVID-19 case with higher serum KL-6, for example, ≥300 U/ml during hospitalization, a linear correlation of KL-6 between the two intervals were also found (Pearson r = .794, p < .001), and a linear regression model predicted KL-6 at greater than 100 days postonset = 106.8 + 0.539 × (KL-6 within 10 days postonset) (r = .836, p < .001, Figure 2). Since the hospital stay of COVID-19 was usually less than a month (Table 1), these data indicated that early serum KL-6 could be a potent predictor for the prognosis of lung injury of discharged patients.

3.3 | Late serum KL-6 was associated with computed tomography lung lesions areas

For those patients conducting computed tomography (CT) examination, we also explored whether there was an association between CT lung lesions areas and the KL-6 values within the previous week (−7 days) and within the next week (+7 days). We found that KL-6 values within the previous week had no significant correlations with lung lesions areas (p > .05, Figure 3A). In contrast, KL-6 values within the next week were linearly correlated to CT left lung, right lung, and left plus right lung lesions areas (p < .001, Figure 3B). Therefore, the late serum KL-6 was correlated to CT lung lesions areas based on our findings.

3.4 | Elevated serum KL-6 was correlated to coagulation dysfunctions

Coagulation dysfunctions have been reported in severe COVID-19 patients. In our cohort, compared to the mild, the coagulation dysfunctions, for example, significantly elevated D-dimer (p = .003) and decreased prothrombin time activity (PTA, p < .001), were observed in severe/critical patients (Table 1). A Spearman’s rank correlation coefficient was calculated to determine the strength and direction of the relationship between KL-6 and coagulation parameters. We found a moderate negative correlation between KL-6 and D-dimer (r = −.427, p < .001) and a significant positive correlation between KL-6 and PTA (r = .500, p < .001). These results suggested that elevated serum KL-6 might be associated with coagulation dysfunctions in severe COVID-19 patients.
correlation analysis revealed that KL-6 was moderately correlated to fibrin degradation product (FDP, \( r = .483 \), \( p < .001 \)), and weakly correlated to D-dimer (\( r = .343 \), \( p < .001 \)), thrombin time (TT, \( r = .305 \), \( p < .001 \)), and fibrinogen (Fib, \( r = .275 \), \( p < .001 \), Table S3). For mild patients, KL-6 was weakly correlated to TT (\( r = .227 \), \( p = .008 \)), D-dimer (\( r = .200 \), \( p = .011 \)), and Fib (\( r = .188 \), \( p = .029 \)) (Table S3). Actually, for most mild patients, the coagulation indexes were normal during most of the hospital stay, as shown in Figure S5. For severe/critical patients, KL-6 was strongly correlated to D-dimer (\( r = .692 \), \( p < .001 \)), FDP (\( r = .641 \), \( p = .001 \)), and moderately correlated to the international normalized ratio (INR) (\( r = .517 \), \( p = .001 \)), PT (\( r = .512 \), \( p = .001 \)), PTA (\( r = .512 \), \( p = .001 \)), and TT (\( r = .423 \), \( p = .008 \)) (Table S3). In contrast to mild patients, an elevated KL-6 was usually accompanied by coagulation dysfunctions among severe/critical patients, as shown in Figure 4, which shows the dynamic profile of KL-6 and coagulation indexes of a severe/critical case. In all, these data suggested a correlation between elevated KL-6 and coagulation dysfunctions among patients with COVID-19.

3.5 Elevated serum KL-6 was correlated to T cells subsets dysfunctions

For all patients with COVID-19, the KL-6 level was negatively correlated to CD3+ T cell counts (Table S3). Of note, the CD3+ T cell count was significantly lower in severe/critical patients than in the mild (median 21.6% vs. 58.4%, \( p < .001 \), Table 1), indicating lymphocytopenia in severe/critical patients. Serum KL-6 was positively correlated to CD4+PD-1+ T cells (\( r = .348 \), \( p < .001 \)), a negative immune climate marker (Table S3). For mild patients, a weak correlation between KL-6 and CD4+PD-1+ T cells (\( r = .273 \), \( p = .003 \)), and CD3+ T cells (\( r = -.325 \), \( p < .001 \)) was found (Table S3). Excessive activation of the immune system and production of inflammatory cytokines, termed as "cytokine storm," was considered to be one of the main causes of lung injury in severe COVID-19 patients.21,22 Here, we showed that among severe/critical patients, serum KL-6 were positively correlated to CD4+CXCR5+ T cells (\( r = .535 \), \( p = .003 \)), and CD4+/CD8+ ratio (\( r = .511 \), \( p = .005 \)), and CD3+CD4+ T cells (\( r = .510 \), \( p = .006 \), as shown in Table S3. With an increase of serum KL-6 among severe/critical patients, the proportion of CD3+CD4+ T helper cells increased, and CD4+CXCR5+ T cells were also upregulated, indicating the lung injury in severe/critical patients was accompanied by an enhanced inflammation response. In contrast, serum KL-6 among severe/critical patients was negatively correlated to Tregs (\( r = -.516 \), \( p = .005 \)), CD3+CD8+ T cells (\( r = -.475 \), \( p = .011 \)), and CD8+CD161+ T cells (\( r = -.425 \), \( p = .034 \)). The dynamic profile of KL-6 and T cell clusters of a severe/critical patient was shown in Figures S6 and S7. These results indicated that among severe/critical COVID-19 patients with elevated KL-6, CD3+CD8+ cytotoxic T cells were excessively depleted, and Tregs was also down-regulated, characterized by weakened immunosuppression and excessive activation of the T cell immunity, which may jointly lead to lung injury of severe/critical COVID-19 patients. Since T cell subsets are usually not determined in clinical course, an elevated KL-6 may be an alternative indicator of immune dysfunctions, especially among severe/critical COVID-19 patients due to their significant correlations.

4 DISCUSSION

In this study, we showed a complete dynamic profile of serum KL-6 among COVID-19 patients from disease onset to postdischarge. In addition, we found that serum KL-6 of discharged COVID-19 patients could be predicted by its value at an early stage (Figure 2), rendering
us an ideal tool to evaluate the prognosis of lung injury of COVID-19. Undoubtedly, pulmonary function testings would provide a more comprehensive assessment of the recovery of discharged patients.

One of the most important questions in controlling COVID-19 is to identify the risk factors of severe illness or death. Here, we confirmed that serum KL-6 was associated with COVID-19 severity in a cohort including 17 severe/critical patients. In addition, we also found a linear correlation between serum KL-6 and CT lung lesions areas, which links to COVID-19 progress. Therefore, COVID-19 patients with an elevated KL-6 level on admission deserve a close observation in case of progression.

Coagulation dysfunctions like high D-dimer levels on admission have been proved to be associated with poor overall survival. Innate immune response to SARS-CoV-2, dysfunctional ACE2, and inflammation activation may participate in the coagulation dysfunctions, but the specific mechanism is unknown. Here, we demonstrated that KL-6 was correlated to coagulation indexes, for example, among severe/critical patients, KL-6 was strongly correlated to D-dimer ($r = .692, p < .001$) and FDP ($r = .641, p = .001$, Table S3), both of which have been suggested as risk factors of COVID-19 severity. It is worth noting that for mild patients, KL-6 was weakly correlated to some coagulation indexes (Table S3), which were normal during most of the hospital stay (Figure S5), and serum KL-6 of some mild patients remained low from symptom onset (Figure S1). So the interpretation of these correlations in mild patients should be careful.

The role of host immunity in COVID-19-associated morbidity and mortality remains controversial. It is generally considered that over-activation of the immune system termed as "cytokine storm" mediates lung injury, while another study hold that immunosuppression characterized COVID-19 infections. In this cohort, compared to mild COVID-19, the severe/critical patients had significantly lower CD3+ T cells and CD3+CD4+ T cells, and significantly higher Tregs and CD4+PD-1+ T cells, supporting immunosuppression in them. Because we did not determine the immunological indexes of healthy control here, whether immunosuppression also occurred in mild patients remains unclear. We found that KL-6 was negatively correlated to CD3+ T cells ($r = -.325, p < .001$) and positively correlated to CD4+PD-1+ T cells ($r = .273, p = .003$) among mild patients, indicating that lung injury was likely associated with immunosuppression in this population. However, this result should be interpreted with caution because the correlation coefficients are weak and as mentioned above, we did not determine whether immunosuppression indeed occurred in mild patients. The elevation of KL-6 in severe/critical patients was correlated to over-activation of immunity, for example, KL-6 was positively correlated to CD4+CXCR5+ T cells, and CD4+/CD8+ ratio, CD3+CD4+ T cells, and negatively correlated to Tregs, CD3+CD8+ T cells, and CD8+CD161+ T cells (Table S3). These findings may explain why dexamethasone, a kind
of immunosuppressants, resulted in lower mortality among severe COVID-19 patients.33

The limitations of our study include that there were a small number of severe/critical patients (n = 17, 10.2% [17/166]) compared to the mild (n = 149, 89.8% [149/166]) included in the cohort (n = 166). The percentage of severe/critical patients here (10.2%) may represent the real proportion of it in natural SARS-CoV-2 infection in Guangzhou, as a previous study conducted by China Medical Treatment Expert Group for COVID-19 reported that the proportion of severe cases in mainland China were 15.7% (173/1099),34 which was similar to that in our study. By now the cumulative number of locally confirmed cases in Guangzhou was 377 according to National Health Commission Report.35 Thus, collecting lots of severe/critical patients in this region seems difficult.

In summary, our findings support KL-6 as a biomarker of COVID-19 severity, and also a predictor of the prognosis of lung injury of discharged patients. The dynamic profile of KL-6 was closely correlated to coagulation disorder and immune dysfunction, especially among severe/critical patients, highlighting the possibility that coagulation disorder and immune dysfunction may be a contributor to lung injury of COVID-19, and the underlying mechanism requires further research.

ACKNOWLEDGMENTS

This study was supported by Guangdong Provincial Department of Science and Technology Fund (No. 2020B111330002). The authors would like to thank Guangzhou Kangrun Biotech Co. for their technical assistance.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

Xiaoping Tang, Fengyu Hu, and Feng Li conceived the study and supervised all aspects of the study. Kai Deng, Qinghong Fan, Yanhong Yang, Xizi Deng, Ruiying He, Yizhou Tan, Yun Lan, Xilong Deng, Yuejun Pan, Yaping Wang, Yujuan Guan, Huiyuan Liu, Fengjuan Chen, Xiaoneng Mo, Xinghua Tan, Chun Luo, Xueliang Wen, Ying Liu, Jinxin Liu, and Lieguang Zhang participated in the experiment. Kai Deng, Qinghong Fan, Yanhong Yang, Yaping Wang, and Fengjuan Chen collected the data. Xiaoping Tang, Fengyu Hu, Feng Li, Kai Deng, and Qinghong Fan analyzed the data and prepared the manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Feng Li http://orcid.org/0000-0002-7690-8870

REFERENCES

1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed October 30, 2020.

2. Ziegler CG, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016-1035.

3. Yao XH, He ZC, Li TY, et al. Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. Cell Res. 2020;30(6):541-543.

4. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517-1520.

5. Qian Z, Travanty EA, Oko L, et al. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 2013;48(6):742-748.

6. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020;93:250-256.

7. Huang H, Cai S, Li Y, et al. Prognostic factors for COVID-19 pneumonia progression to severe symptoms based on earlier clinical features: a retrospective analysis. Front Med. 2020;7:557453.

8. Levi M, Thachil J, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438-e440.

9. Nakajima H, Harigai M, Harai M, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27(5):1164-1170.

10. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995;108(2):311-315.

11. d’Alessandro M, Bergantini L, Cameli P, et al. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. Biomark Med. 2020;14(8):665-674.

12. d’Alessandro M, Cameli P, Refini RM, et al. KL-6 concentrations as a novel biomarker of severe COVID-19. J Med Virol. 2020;92:2216-2220.

13. Nakamura H, Miyagi K, Otsuki M, et al. Serum KL-6 can distinguish between different phenotypes of severe COVID-19. J Med Virol. 2020;93:158-160.

14. d’Alessandro M, Bergantini L, Cameli P, et al. Peripheral biomarkers’ panel for severe COVID-19 patients [published online ahead of print October 2, 2020]. J Med Virol. 2020.

15. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.

16. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.

17. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

18. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934-943.

19. Kandcr T. Coagulation disorder in COVID-19. Lancet Haematol. 2020;7:e630-e632.

20. Singh P, Schwartz RA. Disseminated Intravascular coagulation: a devastating systemic disorder of special concern with COVID-19. Dermatol Ther. 2020;33:e14053.

21. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.

22. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm: what we know so far. Front Immunol. 2020;11:1446.

23. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19—studies needed. N Engl J Med. 2020;382(13):1194-1196.

24. Li M, Lei P, Zeng B, et al. Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease. Acad Radiol. 2020;27(5):603-608.
25. Fei Y, Tang N, Liu H, Cao W. Coagulation dysfunction: a hallmark in COVID-19. *Arch Pathol Lab Med*. 2020;144:1223-1229.

26. Lin J, Yan H, Chen H, et al. COVID-19 and coagulation dysfunction in adults: a systematic review and meta-analysis. *J Med Virol*. 2021;93:934-944.

27. Wang J, Saguner AM, An J, Ning Y, Yan Y, Li G. Dysfunctional coagulation in COVID-19: from cell to bedside. *Adv Ther*. 2020;37(7):3033-3039.

28. Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief review of the risk factors for covid-19 severity. *Rev Saude Publica*. 2020;54:60.

29. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. *Cytokine Growth Factor Rev*. 2020;53:25-32.

30. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. *J Infect*. 2020;80(6):607-613.

31. Soy M, Keser G, Atagunduz P, Tabak F, Atagunduz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. *Clin Rheumatol*. 2020;39(7):2085-2094.

32. Remy KE, Mazer M, Striker DA, et al. Severe immunosuppression and not a cytokine storm characterize COVID-19 infections. *JCI Insight*. 2020;5:e140329.

33. Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report [published online ahead of print July 17, 2020]. *N Engl J Med*. 2020.

34. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382:1708-1720.

35. http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml. Accessed September 30, 2020.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Deng K, Fan Q, Yang Y, et al. Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis. *J Med Virol*. 2021;93:2505–2512. https://doi.org/10.1002/jmv.26793